Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss: results from a 2-phase dietary intervention study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss : results from a 2-phase dietary intervention study. / Valsesia, Armand; Kulkarni, Sameer S; Marquis, Julien; Leone, Patricia; Mironova, Polina; Walter, Ondine; Hjorth, Mads Fiil; Descombes, Patrick; Hager, Jörg; Saris, Wim H; Astrup, Arne; Darimont, Christian; O'Callaghan, Nathan J.
In: American Journal of Clinical Nutrition, Vol. 109, No. 4, 2019, p. 1029-1037.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss
T2 - results from a 2-phase dietary intervention study
AU - Valsesia, Armand
AU - Kulkarni, Sameer S
AU - Marquis, Julien
AU - Leone, Patricia
AU - Mironova, Polina
AU - Walter, Ondine
AU - Hjorth, Mads Fiil
AU - Descombes, Patrick
AU - Hager, Jörg
AU - Saris, Wim H
AU - Astrup, Arne
AU - Darimont, Christian
AU - O'Callaghan, Nathan J
N1 - CURIS 2019 NEXS 126 Copyright © American Society for Nutrition 2019.
PY - 2019
Y1 - 2019
N2 - Background: Several studies recently reported contradicting results regarding the link between amylase 1 (AMY1) copy numbers (CNs), obesity, and type 2 diabetes.Objective: The aim of this study was to assess the impact of AMY1 CN on anthropometrics and glycemic outcomes in obese individuals following a 2-phase dietary weight loss intervention.Methods: Using the paralog ratio test, AMY1 CNs were accurately measured in 761 obese individuals from the DiOGenes study. Subjects first underwent an 8-wk low-calorie diet (LCD, at 800 kcal/d) and then were randomly assigned to a 6-mo weight maintenance dietary (WMD) intervention with arms having different glycemic loads.Results: At baseline, a modest association between AMY1 CN and BMI (P = 0.04) was observed. AMY1 CN was not associated with baseline glycemic variables. In addition, AMY1 CN was not associated with anthropometric or glycemic outcomes following either LCD or WMD. Interaction analyses between AMY1 CN and nutrient intake did not reveal any significant association with clinical parameters (at baseline and following LCD or WMD) or when testing gene × WMD interactions during the WMD phase.Conclusion: In the absence of association with weight trajectories or glycemic improvements, the AMY1 CN cannot be considered as an important biomarker for response to a clinical weight loss and weight maintenance programs in overweight/obese subjects. This trial was registered at www.clinicaltrials.gov as NCT00390637.
AB - Background: Several studies recently reported contradicting results regarding the link between amylase 1 (AMY1) copy numbers (CNs), obesity, and type 2 diabetes.Objective: The aim of this study was to assess the impact of AMY1 CN on anthropometrics and glycemic outcomes in obese individuals following a 2-phase dietary weight loss intervention.Methods: Using the paralog ratio test, AMY1 CNs were accurately measured in 761 obese individuals from the DiOGenes study. Subjects first underwent an 8-wk low-calorie diet (LCD, at 800 kcal/d) and then were randomly assigned to a 6-mo weight maintenance dietary (WMD) intervention with arms having different glycemic loads.Results: At baseline, a modest association between AMY1 CN and BMI (P = 0.04) was observed. AMY1 CN was not associated with baseline glycemic variables. In addition, AMY1 CN was not associated with anthropometric or glycemic outcomes following either LCD or WMD. Interaction analyses between AMY1 CN and nutrient intake did not reveal any significant association with clinical parameters (at baseline and following LCD or WMD) or when testing gene × WMD interactions during the WMD phase.Conclusion: In the absence of association with weight trajectories or glycemic improvements, the AMY1 CN cannot be considered as an important biomarker for response to a clinical weight loss and weight maintenance programs in overweight/obese subjects. This trial was registered at www.clinicaltrials.gov as NCT00390637.
KW - Faculty of Science
KW - Obesity
KW - Insulin resistance
KW - Low-calorie diet
KW - Copy number
KW - AMY1
KW - Weight loss
U2 - 10.1093/ajcn/nqy363
DO - 10.1093/ajcn/nqy363
M3 - Journal article
C2 - 30982860
VL - 109
SP - 1029
EP - 1037
JO - American Journal of Clinical Nutrition
JF - American Journal of Clinical Nutrition
SN - 0002-9165
IS - 4
ER -
ID: 216822857